Premium
Single intravenous administration of the H + , K + ‐ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man
Author(s) -
SIMON B.,
MÜLLER P.,
BLIESATH H.,
LÜHMANN R.,
HARTMANN M.,
HUBER R.,
WURST W.
Publication year - 1990
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1990.tb00468.x
Subject(s) - pentagastrin , stimulation , gastric acid , pharmacokinetics , medicine , endocrinology , volume of distribution , secretion , distribution (mathematics) , pharmacology , dose–response relationship , atpase , enzyme inhibitor , enzyme , chemistry , biochemistry , mathematical analysis , mathematics
SUMMARY The effects of the H + , K + ‐ATPase inhibitor BY 1023/SK&F 96022 on pentagastrin‐stimulated acid secretion have been studied in healthy male volunteers ( n = 12). The gastric acid response to submaximal pentagastrin‐stimulation (0.6 μg/h/kg b.w.) was dose‐dependently inhibited. A single dose of 5 mg decreased acid output by 22% while after 60 mg and 80 mg secretion was almost completely abolished. A good dose linearity was observed for AUC (0, >) and C max over the dose range from 5 to 80 mg. Elimination half‐life, total clearance and volume of distribution of the parent compound were independent of the dose. The drug was well tolerated up to the highest dose of 80 mg. No clinically relevant influence was found on either laboratory screen or cardiovascular parameters.